The A-myb transcription factor shows a restricted tissue distribution and is cell cycle regulated. Furthermore its deregulation has profound eects on the growth and/or dierentiation of the cells in which it is normally expressed. We have therefore characterized its promoter. A 12 kb genomic clone was isolated that comprises the ®rst exon, part of the ®rst intron as well as upstream regulatory sequences. Multiple transcription start sites have been identi®ed which operate in both B lymphocytes and epithelial cells and the upsteam region was shown to have promoter, activity. The boundaries of the minimal promoter region (7183714), of a positive upstream (75387183) and a negative downstream regulatory region (NRE) (+83+374) have been de®ned. The NRE is promoter-and orientation-independent but position speci®c. The A-myb minimal promoter is GC-rich, does not contain any TATA box but has a functional CCAAT box. The CCAAT box and minimal promoter is highly conserved in the corresponding murine sequence. The CCAAT box eciently binds the NF-Y complex and its mutation decreases basal promoter activity by 50%. Two Sp1 binding sites are present upstream from the CCAAT box which can bind Sp1 and contribute to A-myb promoter activity by 70 and 30%, respectively. The two Sp1 sites and CCAAT box together contribute to over 80% of A-myb basal promoter activity and are therefore the major regulatory elements. Finally, we show that the promoter is cell cycle regulated and that the SP1 and CCAAT elements are required for S phase induction. Oncogene (2000) 19, 3931 ± 3940.
Introduction
A-myb belongs to the myb family of transcription factors which include c-myb, B-myb and the v-myb oncogene (Introna et al., 1994; Nomura et al., 1988; Graf, 1992; Takahashi et al., 1995; Foos et al., 1994; Reddy, 1997, 1999) . A-myb expression is ®nely regulated. In both mice and man, this gene is expressed in restricted tissues, mature B lymphocytes, spermatocytes, mammary gland epithelial cells and some neuronal cells (Trauth et al., 1994; Mettus et al., 1994; Golay et al., 1994a) . In these cells A-myb expression is switched on and o at very precise moments of their dierentiation (Latham et al. 1996; Golay et al., 1996; and in some cell types, such as B cells, A-myb has been shown to be also regulated during the cell cycle, being present only during the S, G2 and M phases (Golay et al., 1998; Ziebold and Klempnauer, 1997; Marhamati et al., 1997) . Furthermore, regulation of expression of A-myb is crucial for the normal growth and dierentiation of the cell types in which it is normally expressed. A-myb knock out mice have a defect in spermatogenesis and mammary gland formation (Toscani et al., 1997) . A-myb transgenic mice on the other hand show an accumulation of mature germinal center B cells with follicular hypertrophy (DeRocco et al., 1997) . A-myb may play a role in the biology and/or pathogenesis of some neoplasia: it is highly expressed in most Burkitt's lymphoma cells, and in a fraction of chronic lymphocytic leukaemias (Golay et al., 1996) . The latter ®nding is particularly intriguing since these cells are not proliferating and do not show any of the characteristics of normal germinal center B cells, the population that normally expresses this gene .
The CCAAT box is a common motif present in many eukaryotic promoters. Although many proteins have been described that bind CCAAT elements, NF-Y appears to be the major factor recognizing true CCAAT boxes located in the 760 to 7130 region of promoters (Maity and de Combrugghe, 1998) . NF-Y is a ubiquitous trimeric transcription factor composed of three subunits, NF-YA, -YB and -YC. Although NF-Y is ubiquitous, it also participates in the regulation of some promoters in a lineage-and activation-speci®c manner, perhaps in part through regulation of NF-YA expression (Farina et al., 1999; Bolognese et al., 1999) . It is unable by itself to activate transcription but increases the activity of neighbouring enhancer motifs and participates in the correct positioning of other transcription factors at the start site. Indeed both Sp1 and NF-Y appear to be crucial regulatory elements in several cell cycle regulated genes and may in some cases cooperate with each other (Zwicker and MuÈ ller, 1997; Wright et al., 1995; Sala et al., 1999) .
The unique and highly regulated expression pattern of A-myb in normal and neoplastic cells and the possible deregulation of the gene in some neoplasias such as CLL have led us to isolate and start characterizing its promoter region. Here we describe the transcription start sites, the minimal promoter, an upstream positive and downstream negative regulatory region. We de®ne one functional NF-Y binding CCAAT box and two crucial Sp1 sites.
Results

Isolation and structural characterization of the 5' upstream region of the A-myb gene
In order to identify the promoter region of the A-myb gene, a human genomic library was screened with a 5' fragment from the human A-myb cDNA spanning nucleotides 20 ± 330 of the published sequence (Nomura et al., 1988) . A 12 kb lambda clone was identi®ed and further characterized. The deduced restriction map of the 12 kb lambda clone containing the 5' region of the A-myb gene is shown in Figure 1a . The region completely sequenced is shown by arrows (GenBank Accession Number: AF149089). Sequencing revealed the location of the presumed ®rst exon within a 2.8 kb HindIII fragment (Figure 1a) , that contains the 5' of the previously published A-myb cDNA. The sequence of the ®rst exon diverges 20 nucleotides downstream from the ATG where the ®rst intron initiates (data not shown). This exon ± intron junction contains the expected GT sequence. Except for the ®rst exon, the sequence showed no signi®cant homology to other known sequences. The sequence comprising about 780 nucleotides upstream from the ATG is shown in Figure  1b . Screening of the data bank for potential transcription factor binding sites of this region revealed a consensus CCAAT box and two potential Sp1 sites 500 ± 600 nucleotides upstream from the ATG ( Figure  1b ). This region is also GC rich suggesting that it contains the promoter region of A-myb. This would also be in agreement with the observation that the published A-myb cDNA contains 4890 bp and the major mRNA transcript is 5 ± 5.5 kb (Golay et al., 1996) . The presumed promoter has no consensus TATA box.
In order to determine whether this region is conserved across species, the equivalent murine clone was isolated and sequenced. The alignment of the mouse and human sequences is shown in Figure 1b , revealing a 70% identity with the 780 nucleotide long human sequence and 89% identity in the region surrounding the Sp1 and CCAAT boxes (7183 to +1). These data suggest that this region does indeed contain important functional elements.
Identification of the transcription start sites
In order to localize the transcription start site(s) ®ve RNA probes were generated to carry out RNase protection assays (Figure 2a) . Four of these probes (A ± D) are overlapping and cover about 500 bp upstream from the start of the previously published cDNA. The ®fth probe (E) covers about 250 bp 1 kb upstream from the cDNA. Total RNA from normal buoyant tonsillar B cells (Figure 2b , lanes 1), from an A-myb negative Burkitt's lymphoma cell line (lanes 2) (Golay et al., 1996) and yeast tRNA as negative control (lanes 3) were used in RNase protection assays. Probe A, which does not include the CCAAT box (Figure 2a ), was completely protected: the size of the band, deduced from a sequence run in parallel, a b Figure 1 Characterization of the A-myb promoter (a) Schematic illustration of the 12 kb lamdba clone containing the 5' portion of the human A-myb gene and restriction enzyme map. The enlargement below represents the 2.8 kb subclone that includes the 5' end of the A-myb cDNA, the promoter region and part of the ®rst intron. (b) DNA sequence of a 780 nucleotide genomic fragment spanning the human A-myb promoter and part of the ®rst exon. Positions are numbered from the major transcription start site. Arrows indicate the transcription start sites identi®ed by RNase protection. The sequence from the corresponding murine clone is shown below. Shaded nucleotides correspond to the 5' of the published cDNAs (Nomura et al., 1988) . The CCAAT and Sp1 consensus sequences are boxed. Arrow heads demarcate the 5' or 3' end points of dierent constructs corresponded exactly to the expected size of the complete probe (Figure 2a,b) . On the other hand probe B, which covers the CCAAT box as well as the upstream 26 nucleotides, gave a clear and reproducible pattern of protection which was absent in the negative controls (Figure 2b ). The series of bands obtained was unlikely to be due to degradation of the RNA, since the same set of bands was obtained in several independent experiments with probe B but not with probe A. In order to con®rm that the bands were due to multiple transcription start sites, two further probes, partially overlapping with probe B, were prepared. These two probes, C and D, have identical 3' end but dierent 5' ends ( Figure 2a ) and showed, as expected, identical patterns of protected bands (Figure 2b and data not shown). The lengths and pattern of the bands obtained with probes C and D corresponded exactly to the bands obtained with probe B, except that they were shorter by 65 nucleotides (which corresponds to the distance between the 3' ends of probes C/D relatively to probe B) (Figure 2a,b) . These data thus con®rm unambiguously that multiple transcription start sites are present. These sites are clustered in three distinct areas. The most intense bands (cluster`a') are located about 93 ± 98 bp downsteam from the CCAAT box. The second and third groups of initiation sites (clusters b' and`c') are positioned 50 ± 70 and 20 ± 30 bp downstream from the CCAAT box, respectively (Figures 1b and 2b) . The most intense initiation site was arbitrarily designated as +1 (Figure 1b) . Of note is that some residual protection of the full-length probes remains in all experiments (accounting for approximately 9% of transcripts). This suggests the possible presence of additional initiation sites further upstream. In order to investigate this, we used probe E which covers a region about 500 bp upstream from probe C (Figure 2a) . Probe E was completely protected (data not shown) suggesting that these other minor initiation sites are present at least 1 kb further upstream from those described above.
We also analysed the use of transcription start sites in leukaemic B cells or in other cell types that express A-myb. As shown in Figure 2b , the same pattern of bands was obtained with probe B using mRNA puri®ed from a Burkitt's lymphoma (Ramos, lane 4), a follicular lymphoma (DHL-4, lane 5) and a mammary adenocarcinoma line (MDAMB231, lane 6). This shows that dierent neoplastic or normal cell types expressing A-myb use the same set of transcription initiation sites.
In order to con®rm the location of the transcription start sites we also carried out 5' race experiments using A-myb speci®c oligonucleotides. The screening of about 200 clones led to the isolation of three clones speci®c for A-myb. Their sequence con®rmed the presence of multiple transcription start sites in the region 747 to +6 (data not shown).
In conclusion we have identi®ed multiple transcription initiation sites 20 ± 100 bp downstream from the putative CCAAT box, thus con®rming that we have isolated the promoter region of A-myb.
Functional analysis of the A-myb promoter in different cell types
In order to test the functionality of the isolated Amyb genomic sequences and identify the promoter region, a series of constructs was prepared covering the region from 75930 to +374, all including the CCAAT box and transcriptional initiation sites, and placed upstream from the luciferase reporter gene. The transcriptional activity of the constructs was tested in the BJAB Burkitt's lymphoma line, which normally expresses high levels of A-myb. As shown in Figure  3a , the longest construct (75930 to +374) showed relatively weak activity (threefold over pGL3 basic activity). Progressive deletion on the 5' of this region up to position 7538 led to a progressive increase in activity up to about eightfold over the control. These data show that the A-myb promoter is contained within the 7538 to +374 region. The region from 7538 to 75930 may contain negative elements or may decrease promoter activity due to its rather large size. Having isolated a region (7538 ± +374) with promoter activity, we carried out further 5' and 3' deletions to analyse it in more detail. Deletion on the 5' to 7236 and 7183 decreased activity by 25 and 45% respectively, showing that the region from 7538 to 7183 contains a positive element for transcription ( Figure 3b ). On the contrary deletion of the 3' region, including nucleotides 714 to +374, increased promoter activity by about fourfold (Figure 3b ). These data show that the 714 to +374 sequence contains a strong negative regulatory element (NRE). Thus the construct carrying the positive element and lacking the negative one showed the highest activity (7538 to 714), of about 30-fold over background. Again 5' deletions up to position 7183 in constructs lacking the NRE progressively decreased activity, con®rming the presence of a positive element in the 7538 to 7183 region. Further deletion on the 5' to position 7126 led to a complete loss of transcriptional activity. Thus the sequence from 7183 to 7126 contains crucial elements for transcriptional activity. On the basis of these results we de®ne the boundaries of the minimal promoter from 7183 to 714. This region contains the CCAAT box and two Sp1 sites ( Figure 1b ). Finally we have also veri®ed that A-myb promoter construct 7538/714 uses the same set of initiation sites as the endogenous A-myb gene by performing RNase protection assays on RNA isolated from cell transfected with this construct (data not shown).
Since the NRE was included between nucleotide 714 and +374, and its removal deleted one group of transcriptional start sites (cluster`a', Figure 1b) , we constructed another plasmid that deleted only the +82 to +374 sequence and thus maintained all transcription initiation sites. As shown in Figure 3b , the activity of this construct was not signi®cantly dierent from that of the corresponding construct (7236 to 714) with a larger 3' deletion. We conclude that the NRE is located within the +83 to +374 sequence.
In order to determine more precisely the nature of the NRE, we have constructed further plasmids carrying this element (+5 to +374) in the reverse orientation (A-myb ± NRE inv) downstream from the A-myb promoter or in the correct orientation either downstream (SV40 ± NRE) or upstream (NRE ± SV40) from the SV40 heterologous promoter. As shown in Table 1 , the element showed similar (4 ± 7-folds) inhibitory activity when placed downstream from the A-myb or SV40 promoters and in either orientation, but was inactive upstream. We conclude that the NRE is promoter and orientation independent but position speci®c.
In order to determine whether any of the positive or negative elements identi®ed could be responsible for the cell type speci®c expression of A-myb, the major constructs were also tested in a T cell line (Jurkat) and in ®broblasts (NIH3T3). As shown in Figure 4 , the relative activities of the dierent constructs were not signi®cantly dierent in the dierent cell types. These data suggest that the region analysed does not contain tissue speci®c regulatory elements.
We have thus identi®ed a functional A-myb promoter, de®ned the boundaries of the minimal promoter region between nucleotides 7183 and 714, and localized an upstream positive regulatory region between 7538 and 7183. We have also identi®ed a downstream NRE between +82 and +374 which is position speci®c but orientation and promoter independent.
The A-myb minimal promoter contains a functional CCAAT box that binds NF-Y The minimal promoter identi®ed above was found to contain a consensus CCAAT box as well as two Sp1 sites. In order to determine whether the consensus CCAAT box identi®ed 20 ± 100 bp upstream from the transcription start sites was functional, we ®rst investigated whether it was capable of binding the CCAAT box binding tripartite protein complex NF-Y in band shift assays. As shown in Figure 5 , lanes 1 ± 6, increasing amounts of unlabelled A-myb CCAAT box oligonucleotide were able to eciently compete for binding of NF-Y to a standard labelled Y-box oligonucleotide, whereas an irrelevant oligonucleotide was not. A 200-fold excess cold A-myb CCAAT box completely inhibited binding of NF-Y to Y-box. In addition, NF-Y was able to bind to labelled A-myb CCAAT box and this binding was competed nearly equally well by cold A-myb CCAAT box as by cold Ybox itself ( Figure 5 , lanes 7 ± 14). Finally to demonstrate formally that the complex bound was indeed NF-Y, a supershift experiment was carried out using the labelled A-myb CCAAT box and antibodies against the three dierent components of the NF-Y complex, A, B and C (Mantovani et al., 1992) . As shown in Figure 5 , lanes 15 ± 19, all three antibodies completely supershifted the A-myb CCAAT box complex, whereas an irrelevant antibody was inactive. We conclude that the A-myb CCAAT box can bind brugghe, 1998; Mantovani, 1998) . In order to determine whether the A-myb CCAAT box is functionally important for promoter activity, we have mutagenized it in the context of both the 7183/ 714 minimal promoter construct, as well as the transcriptionally more active 7538/714 background. We then tested the transcriptional activity of the mutant versus the wt constructs in the BJAB cell line by transient transfection. As shown in Table 2 , the CCAAT mutant showed a 50 ± 75% decrease in activity relative to wt demonstrating that the CCAAT box is indeed functional.
We conclude that the A-myb CCAAT box can eciently bind the NF-Y complex and that this binding is important for full promoter activity.
Two Sp1 sites within the minimal promoter region are required for A-myb promoter activity
We had also identi®ed two consensus Sp1 binding sites 57 and 27 nucleotides upstream from the CCAAT box, designated Sp1-I and Sp1-II respectively, and have investigated their role for A-myb promoter activity. We ®rst carried out band shift assays to demonstrate that they bind Sp1. As shown in Figure 6 , labelled oligonucleotides corresponding to the Sp1-I (panel A) or Sp1-II (panel B) sequences formed a complex which was competed eciently by itself or by a cold consensus Sp1 oligonucleotide (lanes 1 ± 3). The same complex was not competed by the same oligonucleotide containing a mutation within the Sp1 site ( Figure 6 , lanes 4). Finally, both the Sp1-I and -II complexes were supershifted with an anti-Sp1 antibody (lanes 5) but not with an irrelevant antibody (lanes 6). We can conclude that both the Sp1-I and -II sites can bind to Sp1.
To demonstrate the functionality of the Sp1 sites, we mutagenised them either separately or together in the context of both the minimal (7183/714) and full promoter (7538/714) and the activity of the constructs was investigated by transient transfection in the BJAB cell line. As shown in Table 2 , the single mutagenesis of Sp1-I reduced the basal and full promoter promoter activity by 68 and 65%, whereas mutagenesis of the Sp1-II site reduced activity by 36 and 35% respectively. Mutating both sites together was slightly more eective than mutating only the strongest site I alone, since the inhibition reached with both sites mutated was about 75%. We also tested the activity of the minimal promoter carrying both Sp1 sites as well as the CCAAT box mutated. This triple mutant showed an 80% inhibition of activity relative to wild type. These data altogether show that all three sites contribute to A-myb minimal promoter activity, the Sp1-I having strongest activity, followed by the CCAAT box and the Sp1-II site. Furthermore the ®nding that the introduction of more than one mutation has a stronger eect than a single mutation suggests that all three sites can contribute independently to A-myb promoter activity.
Cell cycle regulation of the A-myb promoter requires the Sp1 sites and CCAAT box
A-myb is known to be induced in S phase (Golay et al., 1998; Ziebold and Klempnauer, 1997; Marhamati et al., 1997) . We therefore investigated whether the promoter that we have identi®ed could be regulated during cell cycle, and whether the Sp1 and CCAAT boxes played a role in this regulation. NIH3T3 cells were transfected with dierent A-myb promoter constructs and luciferase activity was measured either after growth arrest in low serum (G0) or after restimulation in 20% FCS for 16 h (S phase). As shown in Table 3 , all the A-myb promoter constructs tested, 7538/714, 7236/714 and 7183/714, showed a reproducible twofold increase in activity in S relative to G0 phases. This induction was reproducible in several experiments. The empty pGL2 basic vector alone showed no induction. Mutation of the Sp1 Figure 6 Sp1 binds to the A-myb GC boxes. BJAB cell extracts were used in EMSA with labelled Sp1 I oligonucleotide (a) or Sp1-II oligonucleotide (b) (lanes 1). The indicated unlabelled competitor oligos were added at 100 fold molar excess (lanes 2 ± 4): I: Amyb Sp1-I; II: A-myb Sp1 II; cons.: Sp1 consensus; mut: mutated Sp1 site. The complexes were supershifted with the indicated antibodies (lanes 4 and 5). B: bound probe; S: supershifted probe (Table 3 ). The single mutations tested individually showed a weaker and more variable eect (data not shown) suggesting that both Sp1 and CCAAT binding sites are required for full cell cycle regulation.
Discussion
In this study, we describe the isolation, structural and functional characterization of the human A-myb promoter and identify two Sp1 sites and a CCAAT box within the promoter which are required for its basal and cell cycle regulated activity.
The A-myb gene has a very ®ne mode of regulation, since its expression is regulated in a tissue speci®c as well as dierentiation stage speci®c and cell cycle dependent manner: amongst haematopoietic cells Amyb is highly expressed only in mature B lymphocytes present in the dark zone of germinal centres (Golay et al., 1994a (Golay et al., , 1996 Trauth et al., 1994) . These cells are highly proliferating and A-myb is present only in cells that are in the S/G2/M phases of the cell cycle and not in G0/G1 (Golay et al., 1998; Ziebold and Klempnauer, 1997) . However many mature and immature proliferating B cells do not express A-myb, showing that proliferation alone is not sucient to induce Amyb expression (Golay et al., 1994a (Golay et al., , 1998 . Also in the other tissues in which A-myb is detected, i.e. in spermatocytes, mammary gland epithelial cells and some neural cells, A-myb is expressed during a very speci®c dierentiation stage (Trauth et al., 1994; Mettus et al., 1994; Latham et al., 1996) . A-myb RNA levels follow closely protein levels, suggesting that the ®ne regulation of A-myb is mostly at the transcriptional level (Golay et al., 1996) . Thus, the identi®cation of the A-myb promoter, and the de®nition of elements that regulate it, are of a particular interest, also in view of its possible deregulation in some leukaemias or lymphomas (Golay et al., 1996) .
The data presented show that the A-myb promoter is similar to several other cell cycle regulated promoters that lack a TATA box, are GC rich and carry Sp1 and NF-Y binding sites (Zwicker and MuÈ ller, 1997; Sala et al., 1999) . A lack of TATA box is usually associated with a multiplicity of transcriptional initiation sites (Zwicker and MuÈ ller, 1997; Pugh and Tjian, 1991) . We have demonstrated here that NF-Y binds the A-myb CCAAT box and that Sp1 binds two close sites within the minimal promoter, and that all three sites are important functionally contributing to about 50, 68 and 36% of its activity respectively. Mutation of all three sites leads to a reduction of at least 80% of the promoter's activity. NF-Y and Sp1 have been shown to directly interact and cooperate with each other in some promoters (Sundseth et al., 1997; Roder et al., 1997; Wright et al., 1995) . Sp1 has also been shown to bind several other transcription factors such as E2F, AP-1 and Rb (Lin et al., 1996; Karlseder et al., 1996; Noe et al., 1998; Wells et al., 1996; Udvadia et al., 1993; Noti et al., 1996; Sala et al., 1999) . Since mutation of two or three Sp1 and NF-Y sites within the A-myb promoter is always more inhibitory than single or double mutations, we conclude that each site can independently contribute to transcription. However we cannot exclude that some cooperation between NF-Y and Sp1 also takes place in the A-myb promoter.
We have also demonstrated here that the minimal Amyb promoter is cell cycle regulated and that the Sp1 and CCAAT box are required for this regulation. Sp1 is present in the promoter of many house keeping and other genes and was originally thought to be required for basal transcription. More recently, evidence has emerged for a role of Sp1 in the cell cycle regulated or induced expression of several promoters (Black et al., 1999; Birnbaum et al., 1995; Lin et al., 1996; Karlseder et al., 1996; Zwicker and MuÈ ller, 1997) . Thus also in the case of A-myb, a promoter which is cell cycle regulated only at speci®c stages of dierentiation, Sp1 plays a crucial role.
Similarly, it is increasingly clear that NF-Y is involved in the activation of many, if not most, cell cycle regulated promoters (Zwicker and MuÈ ller, 1997; Mantovani, 1998; Saville and Watson, 1998) . Interestingly, promoters active in all dierent phases contain NF-Y sites, close to phase-speci®c regulatory elements: (i) CCAAT boxes are found in G1/S boundary promoters, such as Topoisomerase IIa, TK and E2F-1. These are usually regulated by E2F and E2F-mediated activation preferentially requires cooperation with the natural NF-Y binding site (van Ginkel et al., 1999) . (ii) In the S phase cyclin A, the CCAAT box is close to phase-speci®c boxes (Huet et al., 1996) . (iii) G2/M promoters such as CDC25c, CDC2, cyclin B1 and B2 are controlled by NF-Y (Zwicker et al., 1995a, b; Bolognese et al., 1999; Farina et al., 1999) . In CDC25c and cdc2 CDE-CHR elements are functionally interrelated with CCAAT boxes (Zwicker et al., 1995a,b) . In addition, many cell cycle regulated promoters active in dierent phases of the cell cycle, DNA polymerase a, uracil DNA glycosylase, cdk2, cdk6, contain consensus NF-Y CCAAT boxes (R Mantovani unpublished observations). Consequent with their functional importance, CCAAT boxes are in-vivo footprinted in all phases of the cell cycle (Zwicker et al., 1995a,b; Huet et al., 1996; Bolognese et al., 1999) . Our recent ®nding that NF-Y binding activity varies during the cell cycle, being high in G1/S and decreasing in G2/M, adds yet another level of complexity in the control of CCAAT-containing cell cycle promoters (Bolognese et al., 1999) .
A weak band of completely protected RNA has been observed repeatedly in the RNase protection experiments with all A-myb promoter probes tested, including a probe positioned several hundred base pairs upstream from the major transcription start sites. This suggests that a second minor promoter may be present upstream of the A-myb gene, accounting for 
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Oncogene A-myb promoter characterization V Facchinetti et al about 10% of A-myb mRNA. Similar observations have been reported for pax5, another B speci®c transcription factor (Busslinger et al., 1996) and for the bcl-2 gene (Seto et al., 1988) ; interestingly, in this last case, a similar inhibitory regulatory region is present in the transcribed 5' region of the gene (Young and Korsmeyer, 1993) . Indeed also in the case of bcl-2, the NRE is promoter independent but position speci®c being active only when present downstream from the bcl-2 promoter (Young and Korsmeyer, 1993) . Whether the A-myb NRE acts by inhibiting transcription initiation, by inducing pausing, by altering RNA stability or by inhibiting protein translation will be the subject of future work and is beyond the scope of this study.
The elements so far de®ned and the region analysed for transcriptional activity, which include about 6 kb of DNA on the 5' side of the gene, has not allowed us so far to identify a tissue speci®c regulatory element, since the pattern of activity of the dierent fragments was similar in B lymphocytes, T lymphocytes and ®broblasts. Furthermore the pattern of RNase protection obtained with mRNA from human mammary adenocarcinoma cell lines, suggested that the multiple sites for transcriptional initiation are a characteristic of A-myb expression irrespective of the tissue. Thus, the elements regulating tissue speci®c expression are probably located outside the 6 kb analysed or may require a chromatin environment to be detected (Smith and Hager, 1997; Blackwood and Kadonaga, 1998) .
As exempli®ed by the pax-5 experience, the availability of the genomic regions and detailed functional informations are instrumental for an in-depth study of A-myb expression in human pathology. Indeed we have observed very high levels of A-myb expression only in 80% of Burkitt's lymphomas and in 25% CLL patients (Golay et al., 1996) . In both cases, no major genetic alterations on the coding region of the gene have been detected (Facchinetti et al., unpublished observations) but more detailed work will now be possible to study possible structural damages within the regulatory regions. It is indeed consolidated experience that the majority of the lesions in human lymphomas involve the promoter regions of transcription factors (Rabbits, 1994) . Future work will also include the individuation of functional elements within the positive regulatory region and the characterization of the nature of the negative element.
Materials and methods
Isolation of the 5' flanking region of the human and murine A-myb genes A 330 bp BamHI-ClaI probe corresponding to the 5' end of the A-myb cDNA sequence (Gonda et al., 1987 ) was used to screen 10 6 clones of a human placenta genomic DNA library in the LAMBA FIX vector (Stratagene). A 12 kb positive clone was isolated and after restriction analysis, a 7.8 kb SacI ± XbaI fragment as well as shorter subclones were transferred into the pBluescript II KS+ vector (Stratagene). The dierent subclones were characterized by restriction enzyme analysis followed by Southern blotting and hybridization to speci®c probes and by DNA sequencing using the dideoxy method. For the murine sequence, the RPCI-21 PAC library (BACPAC Resource Center, Oakland, CA USA) was screened with a 260 bp fragment corresponding to the 5' end of the murine cDNA. Clone 456C9 was identi®ed as positive and a 3 kb BgIII fragment from it was subcloned into pBluescript and sequenced.
RNase protection analysis
The human A-myb probes used for RNase protection were generated by subcloning PCR products corresponding to fragments +5 to +305 (probe A), 7126 to +146 (Probe B), 7256 to +81 (probe C), 7183 to +81 (Probe D) and 7853 to 7647 (Probe E) into pBluescript.
Upon linearization with appropriate restriction enzymes, the constructs were transcribed in vitro with T3 or T7 polymerase (MAXIscript, Ambion, Austin, TX USA) to obtain a-32 P-UTP-labelled antisense RNA. The full-length riboprobes were puri®ed from 6% acrylamide gels containing 8 M urea. RNase protection assays were carried out with the RPA II kit (Ambion) according to the manufacturer's instructions, with minor modi®cations. The puri®ed RNA probes were hybridized overnight with 20 mg of total RNA at 428 or 688C, according to their melting temperature. Singlestranded RNA was digested with 5 units/ml RNase A and 200 units/ml RNase T1 for 1 h. Yeast RNA was used as a negative control. The products of the RNase protection assay were analysed on 6% acrylamide gels containing 8 M urea. DNA sequence ladders were used as molecular weight markers.
Plasmid constructs for transient transfection assays
A 6.3 kb SacI ± RsaI fragment corresponding to the (75930 ± +374) region of the A-myb gene was subcloned into the enhancerless, promoterless luciferase reporter vector pGL3-Basic (Promega, Madison, WI, USA). Subfragments of this region were obtained by restriction enzyme digestion creating the 5' deletion constructs with endpoint at positions 72330 (EcoRI), 71230 (HindIII), 7538 (SpeI), 7236 (SacII). The promoter fragments with 5' endpoint at 7183 and 7126 were generated by PCR. The 3' deletion constructs with endpoint at position 714 were obtained from the previously described plasmids by cutting with PstI, while the 3' endpoint at position +82 was obtained by PCR. All constructs that contain the complete 5' untranslated region have identical 3' ends, which were generated by cleavage of the RsaI site, just upstream of the ATG site. The PstI ± RsaI fragment (+5 to +374) was inserted either upstream or downstream of the SV40 promoter in the pGL3 promotervector plasmid (Promega). All constructs were veri®ed by both restriction enzyme digestion and sequencing of the pertinent DNA junctions to verify copy number and orientation of inserts. All PCR-generated fragments were completely sequenced to verify absence of errors.
Site-directed mutagenesis
Mutations in the Sp1 sites and in the CCAAT box were generated by PCR using the technique of Datta (1995) and were con®rmed by sequence analysis. The oligonucleotides used for site-speci®c mutagenesis were: mut sp1 I: dGCGCT-GAGGTATTGGCTGGGGAGC, mut sp1 II: dAAGAAGC-GAGGTATTGGAGGGGAGA, and replaced the core CCGC Sp1 consensus sequence by AATA. The mutant CCAAT box oligonucleotide was dCCCTGAACCTCACGA-GCTGTGGGGGCC replacing the core CAA with TCG.
Cells and cell cultures
The BJAB non-Hodgkin lymphoma line was a gift from Dr Vercelli (Dibit Center, Ospedale San Raaele, Milan, Italy). The T-cell leukemia line Jurkat were from the American Tissue Culture Collection (ATCC; Rockville, MD, USA).
Germinal center-enriched human B cells (large B) were obtained as described previously (Golay et al., 1994a) . Brie¯y total B cells were puri®ed from freshly excised tonsils by rosetting with aminoethylthiouronium-treated sheep red blood cells. The activated buoyant B cells were then puri®ed on a discontinuous Percoll gradient. All lymphoid cells were grown in RPMI 1640 medium (Seromed, Berlin) supplemented with 10% foetal calf serum (Hyclone, Steril System, Logan, UT, USA). NIH3T3 ®broblasts and the human adenocarcinoma NDAMB231 were grown in Dulbecco's modi®ed Eagle's medium (Seromed) supplemented with 10% foetal calf serum (Hyclone). All medium were supplemented with 2 mM L-glutamine (Life Technologies, Inc., Paisley, Scotland) and 50 mg/ml gentamycin (SheringPlough, Milan, Italy).
Transient transfections
All constructs were puri®ed through two rounds of CsCl gradients and transfected into logarithmically growing cells. Transient transfection of the BJAB and Jurkat cells were performed using the DEAE-dextran method as described . NIH3T3 cells were transfected with the Ca phosphate precipitation method (Golay et al., 1994b) . For lymphoid cells, a total of 2.5610 6 cells were transfected per point with equimolar amounts (approximately 1 p.mol) of the luciferase reporter plasmids. In each experiment 3 mg of CMV-b-galactosidase plasmid pON405 was cotransfected to normalize for transfection eciency. The pGL3 control plasmid (Promega), in which the luciferase gene is regulated by the SV40 promoter/enhancer, and the promoterless pGL3-basic (Promega), were always used in parallel transfections as positive and negative controls. After 48 h transfected cells were harvested for luciferase and b-galactosidase assays. Equal amounts of total protein, determined with the Bio-Rad protein assay (Bio-Rad), were used for b-galactosidase and Luciferase assays. Luciferase activity was tested with Luciferase Assay System (Promega) and the light emission was measured with a Berthold Lumat LB 9507 luminometer. Luciferase activities were normalized for transfection eciency as determined by b-galactosidase activity.
For analysis of cell cycle regulation, the major promoter constructs were transfered into the pGL2 basic vector which gives lower background activity in NIH3T3 cells. NIH3T3 cells were transfected as above at 200 000 cells/60 mm dish and then growth arrested in 0.2% FCS. Cell lysates were prepared after 48 h starvation (G0 phase) or following 16 h restimulation in 20% FCS (S phase). Luciferase activity was analysed and normalized as above.
Nuclear extracts preparation and gel shift analysis
To obtain nuclear extracts cells were lysed in hypotonic buer (10 mM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EGTA, 0.1 mM EDTA, 0.5 mM dithiothreitol) supplemented with phenylmethylsulfonyl¯uoride (0.5 mM), pepstatin A (1 mg/ml), leupeptin (10 mg/ml), aprotinin (10 mg/ ml), 1 mM Sodium OrthoVanadate and 0.1% NP40. Nuclei were pelleted and resuspended in hypertonic buer containing 10 mM HEPES pH 7.4, 300 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 0.5 mM dithiothreitol, 10% glycerol and the phosphatase and protease inhibitors described above. Soluble proteins released by 30 min incubations on ice, were collected by centrifugation at 12 000 g for 15 min at 48C, and supernatant was aliquoted and stored at 7758C.
The sequences of oligonucleotides were as follows (coding strand): Sp1 I: (7178) dTCCAGCTCCCCAGCCCCGCCC-TCAGCGCGC (7148). mutated form of Sp1-I: dTCCAGCTCCCCAGCCaataCCTCAGCGCGC. Sp1 II: (7145) dCT-CTCCCCTCCCCGCCCTCGCTTCTTCG (7118). mutated form of Sp1-II: dCTCTCCCCTCCaataCCTCGCTTCTTCG. Consensus Sp1 binding site: dATTCGATCGGGGCGGGG-CAGC. A-myb CCAAT box: (7111) dGCCCCCACAGC-CAATGAGGTTCAGG (787). The MHC class II Ea Y-Box oligonucleotideand binding conditions were as described (Dorn et al., 1987) . Double-stranded oligonucleotide probes were labelled by ®lling with a-32 P-dCTP and Klenow enzyme to a speci®c activity of 1 ± 3610 5 c.p.m./ng. For gel shift assays, 5 ± 7 mg of nuclear extracts prepared from exponentially growing BJAB cells were incubated in binding buer (10 mM HEPES pH 7.4, 80 mM KCl, 0.6 mM EDTA, 1 mM DTT, 0.5 mg/ml bovine serum albumin, 12% glycerol, 0.1% NP40) containing 50 mg/ml of poly(dI/dC) (Sigma) at room temperature for 10 min and then supplemented with 4610 4 c.p.m. (0.2 ± 0.3 ng) of 32 P-labelled oligonucleotide probe for 15 min in a total volume of 20 ml. Unlabelled competing oligonucleotides were added in molar excess 10 min before the addition of the probe. Antibody supershift experiments were performed by preincubating 2 mg of Sp1 or Stat 1 antibody (Santa Cruz) or 200 ng of anti-NF-Y antibodies for 15 min at RT with each binding reaction prior to the addition of the DNA probe. The anity puri®ed anti-NF ± YAc, anti-NF ± YB and anti-NF ± YC antibodies have been described previously (Mantovani et al., 1992; Bolognese et al., 1999) .
Computer-assisted analysis
The presence of putative transcription factor binding sites was evaluated using the MatInspector and TFsearch programs against the TRANSFAC database.
